Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

NDAQ:RVPH - Post by User

Reviva Pharmaceuticals Holdings, Inc.

<< Previous

Bullboard Posts

Post by whytestockson Dec 11, 2024 12:00pm

21 Views

Post# 36356810

BA, RVPH, SSRM, REAL, MGX showing five-day upward surge

JUST IN: $RVPH BA, RVPH, SSRM, REAL, MGX showing five-day upward surge2024-12-11 09:44:23 ET Boeing Co. (BA) BA is trading UP for the last 5 days, and it at trading at $166.71 with volume of 4,490,589 and a one day change of $2.61 (1.59%). Boeing Co. has a 52-week low of 137.03 and a 52-week high of $267.49. The business's 50-day moving average price ...RVPH - BA, RVPH, SSRM, REAL, MGX showing five-day upward surge

<< Previous

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features